![Study on pRPLND in metastatic non-seminomatous germ cell tumors](https://oncodaily.com/pub/uploads/2024/07/download-15-1-e1721655092882.png)
Study on pRPLND in metastatic non-seminomatous germ cell tumors
María Natalia Gandur Quiroga posted on X about recent paper by Ahmad Mousa et al., commenting:
“Study on pRPLND in metastatic non-seminomatous germ cell tumors:
5-year RFS: 72% (pRPLND) vs 92% (pRPLND + AC)
Similar 5-year DSS: 98% (pRPLND) vs 100% (pRPLND + AC)
Higher chemotherapy burden in pRPLND + AC (1.23 vs 2.46 cycles)
Most pRPLND patients do not require additional chemotherapy
ENE and elevated pre-pRPLND STMs associated with higher relapse risk.”
Journal: BJU International
Author: Ahmad Mousa, Lynn Anson-Cartwright, Eshetu G. Atenafu, Michael A.S. Jewett, Philippe Bedard, Di Maria Jiang, Rachel Glicksman, Peter Chung, Padraig Warde, Martin O’Malley, Susan Prendeville and Robert J. Hamilton.
Source: María Natalia Gandur Quiroga/X
Maria Natalia Gandur Quiroga is a Medical Oncologist and Chief of the Division of Genitourinary Medical Oncology at the Ángel H. Roffo Oncology Institute in Buenos Aires, Argentina. She is a Professor of Medicine at the University of Buenos Aires at the Oncologists Post Graduates Studies. Her research focuses on clinical trials with aims to improve the treatment of patients with urologic tumors. She is an active member of the European Association for Cancer Research, Argentinian Medical Association and American Society of Clinical Oncology.